Chinanews.com client, June 5 (Zhang Ni) A few days ago, the National Medical Insurance Bureau issued the "Guidance Opinions on the Establishment of Pharmaceutical Price and Recruitment Credit Evaluation System (Draft for Comment)". List of matters, the specific content includes but not limited to pharmaceutical commercial bribery, abuse of market dominance, manipulation of market prices, violation of contractual agreements, disruption of procurement order, and other violations of laws and regulations, violations of integrity and fair competition. In the process of pricing, bidding, performance, and marketing, pharmaceutical companies that engage in unfair competition and obtain illegitimate benefits through the actions listed in the catalogue will be included in the scope of the evaluation of pharmaceutical prices and credit evaluation of bidding and procurement.